case_images: PMC8453302_01
case_images: A summary of patient's treatment history.
case_images: OTT-14-4833-g0001.jpg
case_images: PMC8453302_01_OTT-14-4833-g0001.jpg
case_images: f0001
case_images: The patient's treatment history is shown in Figure 1.
case_images: Magnetic resonance imaging (MRI) of the liver (upper) and cervical (lower) lesions at treatment milestones. (A) at baseline; (B) two weeks after IMRT directed to pelvis; (C) two months after IMRT directed to neck combined with brachytherapy and platinum-based chemotherapy (PR); (D) seven months after IMRT directed to neck combined with brachytherapy and platinum-based chemotherapy (PD). (E) three months after pyrotinib treatment (SD); (F) seventeen months after pyrotinib treatment (CR). The red arrows in upper and lower panels indicated metastatic live lesion and the primary cervical adenocarcinoma, respectively.
case_images: OTT-14-4833-g0002.jpg
case_images: PMC8453302_01_OTT-14-4833-g0002.jpg
case_images: f0002
case_images: She was diagnosed with stage IVB cervical adenocarcinoma (the red arrow in Figure 2A) with metastases to parametrial lymph node, retroperitoneal lymph node, pelvic lymph node, and neck lymph node. Unfortunately, she developed metastases to liver (the red arrow in Figure 2B) and left supraclavicular lymph node two weeks later. The pelvic magnetic resonance imaging (MRI), abdominal MRI, and chest computed tomography (CT) scans in September 2018 demonstrated partial response (PR) in parametrial lymph node, retroperitoneal lymph node, pelvic lymph node, and metastatic liver tumor (the red arrow in Figure 2C). In February 2019, the patient experienced disease progression with the newly developed metastatic liver lesion (the red arrow in Figure 2D). The patient achieved stable disease in May 2019 (Figure 2E) and the complete response in the metastatic liver tumor (the red arrow in Figure 2F) and metastases to lymph nodes in July 2020.
case_images: Hematoxylin & eosin (H&E)/immunohistochemistry (IHC) staining on the primary cervical adenocarcinoma/neck lymph node. (A) H&E staining on the primary cervical adenocarcinoma; (B) H&E staining on the neck lymph node; (C) IHC staining for HER2 on the primary cervical adenocarcinoma.
case_images: OTT-14-4833-g0003.jpg
case_images: PMC8453302_01_OTT-14-4833-g0003.jpg
case_images: f0003
case_images: Hematoxylin & eosin (H&E) staining showed a primary cervical carcinoma (Figure 3A) and the metastases to neck lymph node (Figure 3B). Immunohistochemistry staining was performed on the primary cervical tumor and demonstrated that 1% of tumor cells were positive for HER2 overexpression (Figure 3C).